MOUNT LAUREL, NJ and SALT LAKE CITY, UT--(Marketwire - January 18, 2011) - CRI Worldwide, LLC (CRI) announced that it has completed the acquisition of Lifetree Clinical Research®, LC (Lifetree), which brings together two of the most highly respected specialized research organizations in the United States.
The combination enriches the early stage clinical research landscape for clients, enabling them to tap into CRI's leadership in psychiatry and patient population studies as well as Lifetree's expertise in pain management and human abuse liability and other complex studies.
The acquisition expands CRI's Clinical Pharmacology capacity to more than 120 beds, making CRI one of the largest providers of patient population Phase I services in the United States. The combined organization will provide sponsors with access to more than 6 million people along with a broad range of psychiatry and neurology research services at three sites located in New Jersey, Pennsylvania, and Utah.
"As they seek to improve returns on research investments, drug companies and CROs increasingly need clinical research sites that can offer highly specialized services and access to patient populations," said Jeffrey Kinell, President and CEO of the combined organization.
About CRI Worldwide, LLC
CRI Worldwide is a leader in clinical research with expertise in Psychiatry, Pediatrics, Pain, and Neurology. Operating from facilities in Philadelphia and Mount Laurel, N.J., CRI conducts inpatient and outpatient clinical research trials in patients and in healthy volunteers. The CRI Phase 1 Units are located inside fully accredited medical and psychiatric hospitals. CRI works with sponsors to assist them in the design and successful execution of drug development plans that expedite the successful transition to Phase II proof of concept. For additional information, visit www.criww.com.
About Lifetree Clinical Research, LC
Located in Salt Lake City, Utah, and founded in 2003, Lifetree offers multi-therapeutic Clinical Trials Management and site expertise in Phase I-IV clinical trials in its state-of-the-art 35,000-square-foot, 60-bed facility. As a leader in Early Stage Research (Phase I-IV) the Lifetree clinical team specializes in Human Abuse Liability, Analgesia Pain Model Development, Sleep Medicine and Addiction. For more information, visit www.lifetreeresearch.com.
Contact Information:
Contact:
Jennifer Sacco
CRI Worldwide
Office: 856-566-5024